Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Jun 27, 2022

Javier Szwarcberg, CEO of Spruce Biosciences, is developing a compound to address the needs of patients with classic congenital adrenal hyperplasia, CAH, a rare disease first diagnosed at birth. Only recently have companies started to explore innovative therapies to improve the standard of care discovered in the early 1960s. Currently, patients manage their conditions with glucocorticoids but often suffer from steroid-related complications.

Javier explains, "What we're trying to do with our drug is to treat the disease. The compound is a small molecule that binds to a receptor in the pituitary and blocks the release of a hormone called ACTH or adrenal corticotropin hormone. By blocking that hormone, you reduce the amount, the stimulation on the adrenals, and the buildup of precursors that are going to lead to a hyperandrogenic state. So our drug treats the disease. Patients, of course, will still need to get steroids daily to supplement the missing cortisol. But the CAH piece of the disease will be well managed. That's the hope."

"The whole pharmaceutical industry and academic community are starting to pay more attention to rare diseases. And back when I started my career in industry, it was all about addressing the totality of a population with, say, hypertension or diabetes or cancer, for that matter. Now there's a realization that companies ought to be more thoughtful, and research ought to be more thoughtful and address the needs of a subset of patients with rare diseases with more kinds of patient-targeted therapies."

@Spruce_Bio #RareDisease #CAH #CongenitalAdrenalHyperplasia #Glucocorticoids

SpruceBiosciences.com

Download the transcript here

Spruce